Pharma Capsules - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Pharma Capsules

Pharmaceutical Technology

Meisssner Launches New Website

Meissner Filtration Products (Camarillo, CA) recently launched its new website, The new site highlights Meissner's line of laboratory products, including its "STyLUX" and "SteriLUX" 25-mm syringe filters and "Ultradyne" and "Steridyne" 50-mm vent filters. The site also describes Meissner's full-scale production elements such as "UltraCap" high-capacity capsules and "EverLUX" filter cartridges. The website allows users to access and download product literature easily. In addition, users can take a virtual manufacturing facility tour through a streaming video link.

ARx Opens Pharmaceutical Manufacturing Facility

ARx (Glen Rock, PA) officially opened its new pharmaceutical manufacturing facility 18 months after breaking ground. The 25,000-ft2 facility is designed to manufacture dissolvable film, transdermal, and buccal drug delivery systems for over-the-counter, prescription, and biopharmaceutical products. The globally-compliant facility triples ARx's manufacturing capacity and laboratory space.

ARx currently supports commercial thin-film products sold in the United States, Canada, and Latin America, including Novartis Consumer Health's "Triaminic" pediatric and infant cough and cold products, "Theraflu" cold and flu products, and "Gas-X" antigas relief products. The current facility increases the company's potential strip output to more than 1.4 billion strips per year.

ARx is a wholly owned subsidiary of Adhesives Research (Glen Rock, PA).


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What impact do mega-mergers of biopharmaceutical companies have on the development of new drugs?
Improves the quality and number of innovative drugs available to patients.
Restricts innovation and the development of new drugs.
Has no impact on drug development.
Do not know.
Improves the quality and number of innovative drugs available to patients.
Restricts innovation and the development of new drugs.
Has no impact on drug development.
Do not know.
Eric Langer Outsourcing Outlook Eric LangerOutsourcing No Longer Just for Cost-Cutting
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerSeeking Alternative Catalyst Solutions
Jill Wechsler Regulatory Watch Jill Wechsler Global Expansion Shapes Drug Oversight
Chris Burgess Statistical Solutions Chris BurgessIs a Sample Size of n=6 a Magic Number?
Sean Milmo European Regulatory WatchSean MilmoRegulating the Environmental Impact of Pharmaceuticals
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Source: Pharmaceutical Technology,
Click here